Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension

NCT06987097 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

410

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary Arterial Hypertension (PAH)

Interventions

DRUG: Ambrisentan
DRUG: Placebo

Sponsor

Nanjing First Hospital, Nanjing Medical University